< Clinical Trials

Cobi-AVM Study - A Phase 2 Study to Assess The Safety and Efficacy of Cobimetinib in Extracranial Arteriovenous Malformations (AVM)

Study Description

Phase 2 study to evaluate the safety and efficacy of cobimetinib in extracranial arteriovenous malformations (AVM).

Study Eligibility

  • Ages 2 years to 80 years of age
  • Extracranial AVM with volumetric measurable disease
  • Must be able to take oral medications

Contact Information: D'Ann Pierce piercecarold@uams.edu